Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Home

Header Top Menu

  • Careers
  • Investors
  • News
    • Press Release Archive
    • Press Statements
    • Podcasts
      • The Antigen Podcast
      • Get Science Podcast
      • Diverse Perspectives Podcast
      • menopause: unmuted
      • Hemcast
    • Contact Media Relations
    • Press Kits & Downloads
      • Company Press Kit
      • Pfizer Oncology Press Kit
      • PSA Narrative
      • RA NarRAtive
      • Rare Disease Gene Therapy Press Kit
      • ATTR-Amyloidosis Press Kit
      • UC Narrative
      • Eczema Inside Out Press Kit
  • Partners
    • Discovery to Pre-candidate
      • Focus Areas
        • Therapeutic Areas
          • Internal Medicine
          • Inflammation and Immunology
          • Oncology
          • Rare Disease
          • Vaccines
        • Therapeutic Modalities and Technology Platforms
          • Drug Safety
          • Gene Therapy
          • Target Sciences
          • Precision Medicine
          • Medicinal Sciences
            • Biologics Product & Process Development
            • Biotherapeutics Discovery
            • Medicine Design
            • Small Molecule Product & Process Development
        • Emerging Science
          • DNA Damage Response
          • Microsatellite Repeat Expansions
          • Senescence
      • Partnering Models
    • Candidate Through Commercialization
      • Focus Areas
        • Internal Medicine
        • Inflammation and Immunology
        • Oncology
        • Rare Disease
        • Vaccines
        • Hospital
    • Pfizer CentreOne
    • Pfizer Ventures
      • Our portfolio

Healthcare Professionals

  • Healthcare Professionals

Connect with Us

  • Connect with Us
    • Email
    • FAQ
    • Privacy Policy (NEW)
    • YouTube
    • Twitter
    • Facebook
    • LinkedIn
    • Instagram
  • Your Health

    • Healthy Living
      • Brain & Nervous System
      • Cardiovascular Health
      • Cold & Flu
      • Digestive Health
      • Healthier Aging
      • Living Tobacco Free
      • Men’s Health
      • Mental Health
      • Nutrition & Fitness
      • Pediatric Health
      • Respiratory Health
      • Skin Health
      • Vaccines & Prevention
      • Women’s Health

    • Disease & Condition
      • Cancer
      • Cardiovascular Diseases & Conditions
      • Diabetes & Metabolic Disorders
      • Immune System Diseases & Conditions
      • Infections & Infectious Diseases
      • Neurological Diseases & Conditions
      • Menopause
      • Rare Disease
      • Vaccine-Related Conditions
      • Skin Diseases & Conditions
      • Atopic Dermatitis
      • Cardiovascular Disease
      • Severe Hypertriglyceridemia

    • Coronavirus disease (COVID-19) Resources

    • Managing your health
      • Caregiving
      • Evaluating Health Information
      • Tracking Your Health
      • Your Medicines
      • Health Literacy

    • Wellness
    Hot Topics

    Maintaining Emotional Well-Being During COVID-19

    Emotional Well-Being Tips for People Living with Chronic Inflammatory Conditions During COVID-19
  • Our Science

    • Driven to Discover the cure

    • Focus Areas
      • Internal Medicine
      • Inflammation & Immunology
      • Oncology
      • Rare Disease
      • Vaccines
      • Anti Infectives

    • Product Pipeline

    • Clinical Trials
      • Guide to Clinical Trials
      • Find a Trial
      • Expanded Access & Compassionate Use
      • Clinical Trials in Children
      • Partnering with Pfizer
      • Trial Data & Results
      • Research Integrity & Transparency
      • Diversity in Clinical Trials

    • R&D Platforms
      • Biosimilars
      • Gene Therapy
      • Medicinal Sciences
      • Precision Medicine
      • Maternal Immunization

    • Collaboration
      • Partner with Pfizer

    • Research sites

    • Coronavirus disease (COVID-19) Resources
      • All COVID-19 Updates
      • Vaccine Efforts
      • Antiviral Efforts
      • Partnerships & Anti-Infective Efforts
      • Supporting the Fight Against COVID-19
    HOT TOPICS

    MRNA VS. CONVENTIONAL VACCINES

    What Makes an RNA Vaccine Different From a Conventional Vaccine?
  • Our People

    • Meet The Experts
      • Scientists
      • Internal Medicine – Metabolic Disease
      • Inflammation & Immunology
      • Oncology
      • Rare Disease
      • Vaccines
      • Medical Professionals

    • The Journey

    • Leadership
      • Executives
      • Board Members
      • Company Fact Sheet

    • Diverse Perspectives
      • Diversity & Inclusion
      • Supplier Diversity
    HOT TOPICS

    Meet our new Chief Patient Officer, Dr. Dara Richardson-Heron

    dr_richardson_300x170.jpg

    Working Together to Empower Women

    VizagWomen_300x170.jpg

    • Hot Topics
  • Our Purpose

    • Commitment to Global Health
      • Expanding Access
      • Strengthening Health Systems
      • Providing Disaster & Humanitarian Relief
      • Unleashing the Power of Our Colleagues
      • Highlighting Individual Voices

    • Protecting People and the Environment
      • Pfizer's Green Journey
      • Product Stewardship
      • EHS Governance
      • EHS Supply Chain
      • Key Performance Indicators
      • Health & Safety
      • Human Rights

    • Positions on Health Policies
      • Ready for Cures
      • How does Pfizer price medicines?
      • Value of Medicines
      • Policy Positions
      • Creating Cures Through Facility Investments

    • Transparency
      • Working with Health Care Professionals
      • Transparency in Grants
      • Code of Conduct
      • Corporate Compliance
      • Sales and Marketing Compliance

    • Independent Grants
      • Competitive Grants Program
      • Independent Medical Education
      • Investigator Sponsored Research
      • Quality Improvement
      • COVID-19 Vaccine Grants

    • Contributions & Partnerships
      • Healthcare Charitable Contributions
      • Lobbying & Political Contributions
    HOT TOPICS

    Pfizer Women’s Resource Group

    Media Name: IWD_Pull_up_Banner_300x170.jpg

    • Hot Topics
  • Our Products

    • Product listing

    • How drugs are made
      • Branded vs. Generic
      • Biologics & Biosimilars
      • Commitment to Quality

    • Distributors
      • Pfizer Distributors
      • Greenstone Distributors

    • Medicine Safety
      • Reporting Adverse Events
      • Making Good Treatment Choices
      • Partnering With Patients
      • Health Literacy
      • Medicine Safety Tips for Patients
      • Counterfeiting
      • Unused Medicines

    • Safety Data Sheets

    • Medical Information Contacts

    • Pfizer Global Supply
    HOT TOPICS

    Universal vs. Single Payer Healthcare

    Media Name: universal_healthcare300x170.jpg
  • Careers

    • Working Here
      • Mission & Purpose
      • Culture
      • Diversity & Inclusion
      • Career Growth & Colleague Development
      • Compensation & Benefits
      • Ensuring Corporate Responsibility
    • Search Jobs
    • Student & Early Career
      • Postdoctoral Program
      • US Summer Student Worker Program
      • Opportunities for Veterans
    • Pfizer365.com
    • Our Hiring & Recruiting Process
      • Frequently Asked Questions
      • Tips for Interviewing at Pfizer
    • Connect With Us
  • Investors

    • Investors Overview
      • Why Invest / Our Story
      • Prospective Investors
      • Fact Sheet
    • Events & Presentations
    • Financials
      • Quarterly Reports
      • Annual Reports
      • SEC Filings
      • Interactive Data Filings
    • Investor News
    • Stock Information
      • Historical Price Lookup
      • Investment Calculator
      • Historical Stock Chart & Data
      • Dividend & Split History
      • Stock FAQs
    • Governance
      • Board Committees and Charters
      • The Pfizer Board Policies
      • Corporate Governance FAQs
      • Contact Our Directors
    • Shareholder Services
      • Stock FAQs
      • Advisory Information
      • Cost Basis Calculator
  • News

    • Contact Media Relations
    • Podcasts
    • Press Kits & Downloads
    • Press Release Archive
    • Press Statements
  • Partners
  • Footer links

    • Footer Aside Section1
      • CAREER-SEEKERS
      • INVESTORS
      • News & Media
      • Partners
    • Footer Aside Section 2
      • Healthcare Professionals
      • Business To Business
      • Change Region
      • Sitemap
    • Footer Aside Section3
      • Twitter
      • Facebook
      • Linkedin
      • Instagram
      • Youtube
    • Footer Aside Section4
      • Contact Us
      • Terms of Use
      • Privacy Policy

The Facts About Pfizer and BioNTech’s COVID-19 Vaccine

The Facts About Pfizer and BioNTech’s COVID-19 Vaccine
OUR SCIENCE/ The Facts About Pfizer and BioNTech’s COVID-19 Vaccine
January 6, 2021

The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheet at www.cvdvaccine.com.

The U.S. FDA authorization of the Pfizer-BioNTech COVID-19 vaccine for emergency use is a significant step forward in our fight against this pandemic. As we begin to distribute our vaccine, here are some key facts and answers to common questions.

  1. What are the ingredients in the Pfizer-BioNTech COVID-19 vaccine?

The Pfizer BioNTech COVID-19 vaccine is a messenger RNA (mRNA) vaccine that has both synthetic, or chemically produced, components and enzymatically produced components from naturally occurring substances such as proteins. The vaccine does not contain any live virus. Its inactive ingredients include potassium chloride, monobasic potassium, phosphate, sodium chloride, dibasic sodium phosphate dihydrate, and sucrose, as well as small amounts of other ingredients.[i] For more information, please visit cvdvaccine.com.

  1. Do mRNA vaccines change a person’s DNA?

No, mRNA is a transient carrier of information that does not integrate into human DNA.[ii],[iii],[iv],[v]

Unlike a traditional vaccine that uses inactivated, dead, or portions of actual virus to spur an immune response, mRNA delivers a message to your body’s cells via a lipid nanoparticle envelope that instructs the cells to generate the spike protein found on the surface of a coronavirus that initiates infection.[vi],[vii] Instructing cells to generate the spike protein spurs an immune response, including generation of antibodies specific to the SARS-CoV-2 spike protein.

  1. Does your vaccine cause infertility?

There are no data to suggest that the Pfizer-BioNTech COVID-19 vaccine causes infertility. It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a very short amino acid sequence in the spike protein of SARS-CoV-2 that is partly shared with a protein in the placenta called syncytin-1. From a scientific perspective, the differences between the two sequences are quite significant, making it very unlikely our vaccine could generate a response that would harm the placenta.[viii],[ix]

  1. What about allergies and the Pfizer-BioNTech COVID-19 vaccine?

In line with CDC recommendations, we did not test our vaccine in people with a history of severe adverse or allergic reactions to a vaccine or a vaccine ingredient. Overall, there were no safety signals of concern identified in our clinical trials, meaning there was no signal of any serious allergic reaction.[i]

Severe allergic reactions have been reported following the Pfizer-BioNTech COVID-19 Vaccine during mass vaccination outside of clinical trials. Pfizer is monitoring and reviewing all reports of severe allergic reaction in coordination with health authorities. The prescribing information has a clear warning/precaution that appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.[ii]  You can also find the latest guidance from the CDC here.

  1. Can your vaccine cause people to develop COVID-19?

No. Pfizer and BioNTech’s COVID-19 vaccine is an mRNA vaccine, which does not use the live virus but rather a small portion of the viral sequence of the SARS-CoV-2 virus to instruct the body to produce the spike protein displayed on the surface of the virus. That spike protein then generates an immune response to the virus to potentially prevent infection. The vaccine does not allow the SARS-CoV-2 virus to replicate and it cannot cause any known illness.[x] No vaccine can cause a patient to develop the disease against which they were vaccinated.[xi]

Potential side effects of the Pfizer-BioNTech COVID-19 vaccine include injection site pain, fatigue, headache, muscle pain, chills, joint pain, fever, injection site swelling, injection site redness, nausea, malaise, and lymphadenopathy (enlargement of the lymph nodes).[xii]

  1. How long will you be watching people who have been vaccinated? How do we know that bad side effects can’t happen long after vaccination, if the vaccine’s only been studied for less than a year?

We will track participants in our phase 3 clinical trial for the next two years following their second dose, in order to document the long-term effectiveness and safety of the vaccine.[xiii]

Our trial is closely monitored by Pfizer and an outside, independent group of experts called a Data Monitoring Committee, or DMC. Trial investigators also monitor participants’ health, and participants in the trial attend regular planned follow-up visits as part of the trial. Pfizer and BioNTech will be conducting additional studies to determine how effective and safe the vaccine is in the real world and among specific risk groups such as healthcare workers and among nursing home residents. The safety of patients is and always will be our number one priority.[xiv]

  1. What can you share about the Pfizer-BioNTech COVID-19 vaccine in pregnant women?

We recognize that developing a potential vaccine for the prevention of COVID-19 for broad use is critically important to combat the pandemic. In line with standard research practice, pregnant women were not enrolled in our trial, so available data on the Pfizer-BioNTech COVID-19 vaccine administered to pregnant women are limited.

However, a recent study in JAMA Network Open compared the outcomes of pregnancies in women that have / have not had SARS-CoV-2 infection, which showed that SARS-CoV-2 infection during pregnancy was not associated with adverse pregnancy outcomes.[xv]

We will evaluate the vaccine in pregnant women in a study starting in Q1 2021, once developmental and reproductive toxicity studies are complete. People who are pregnant or breastfeeding should discuss their vaccination options with their individual health care provider.

  1. When will you be able to share more information about vaccinating those in younger age groups (12-15 and 16-17 years of age)?

We currently have about 1000 participants in the 12-15-year-old age group enrolled in our trial. This controlled approach was agreed to with the FDA to allow for initial safety assessment in a small group. We plan to evaluate and assess these participants after their second dose prior to conducting further enrollment in this age group. Enrollment for 16-17-year old participants will continue as planned and we will share data in due course over the next few months.[xvi]

  1. Does Pfizer and BioNTech’s vaccine cause Bell’s palsy?

Bell’s palsy is a condition that affects the nerves controlling facial muscles and can occur after a viral infection. It is typically temporary and resolves in a few weeks.[xvii] The observed frequency of reported Bell’s palsy in the vaccine group is consistent with the expected background rate in the general population, and there is no indication of a causal relationship at this time. Pfizer and BioNTech together with FDA will continue to monitor for cases of Bell’s palsy as the vaccine is given to larger populations.

 

[i]Pfizer-BioNTech COVID-19 Vaccine (U.S. Food and Drug Administration 2020)

[ii]Schlake (RNA Biology 2012)

[iii]Sahin (Nature Reviews Drug Discovery 2014)

[iv]Karikó (Molecular Therapy 2019)

[v]Karikó (Immunity 2005)

[vi] Reichmuth (Ther Deliv 2016)

[vii] Midoux (Expert Review of Vaccines 2015)

[viii]Placenta: How it works, what’s normal (Mayo Clinic 2020)

[ix]Vaccine Considerations for People who are Pregnant or Breastfeeding (Centers for Disease Control and Prevent 2020)

[i] Polack (The New England Journal of Medicine 2020)

[ii]Pfizer-BioNTech COVID-19 Vaccine EUA Fact Sheet For Recipients and Caregivers (U.S. Food and Drug Administration 2020)

[x] Maruggi (Molecular Therapy 2019)

[xi]Vaccines and Preventable Diseases (Centers for Disease Control and Prevention 2012)

[xii]Pfizer-BioNTech COVID-19 Vaccine EUA Fact Sheet For Recipients and Caregivers (U.S. Food and Drug Administration 2020)

[xiii]C4591001 Clinical Protocol: A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Health Individuals (Pfizer 2020)

[xiv]C4591001 Clinical Protocol: A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Health Individuals (Pfizer 2020)

 

[xvi] Polack (The New England Journal of Medicine 2020)

[xvii]Bell’s Palsy Fact Sheet (National Institute of Neurological Disorders and Stroke 2020)

MORE ON COVID-19
How to stay safe and prevent the spread.

Related Hot Topics
Albert Bourla Reflects on the One Year Anniversary of the COVID-19 Pandemic
Albert Bourla Reflects on the One Year Anniversary of the COVID-19 Pandemic
Albert Bourla On Ensuring Equitable Access to COVID-19 Vaccines
Albert Bourla On Ensuring Equitable Access to COVID-19 Vaccines
Sandy Focuses on Diversity in Our Clinical Trials
Sandy Focuses on Diversity in Our Clinical Trials
An Early Passion for Science and Public Health Inspires Adriana’s Work
An Early Passion for Science and Public Health Inspires Adriana’s Work
“The Ice Man” - The Pfizer Colleague & Dad Who Keeps Our Medicines and Vaccines on Ice
“The Ice Man” - The Pfizer Colleague & Dad Who Keeps Our Medicines and…
KZOO-Vials-in-Tray-2-(1)_380X220.jpg
Distributing Our COVID-19 Vaccine to the World
KZOO_Filling_Line_10_380X300.jpg
COVID-19 Vaccine U.S. Distribution Fact Sheet
Scientists_Image_380X220.jpg
Albert Bourla Discusses Our FDA Submission
Tags
COVID-19
Vaccines
Show
Hide

Footer menu

  • Your Health
    • Healthy Living
    • Disease Conditions
    • Manage Your Health
  • Our Science
    • Therapeutic Areas
    • Product Pipeline
    • Clinical Trials
    • R&D Platforms
    • Collaboration
    • Research SItes
  • Our People
    • Meet the Experts
    • The Journey
    • Leadership
    • Diverse Perspectives
  • Our Purpose
    • Commitment To Global Health
    • Positions on Health Policies
    • Transparency
    • Contributions & Partnerships
  • Our Products
    • Product Listing
    • How Drugs are Made
    • Distributors
    • Global Product Information Contacts

Footer aside

  • Footer Aside Section1
    • CAREER-SEEKERS
    • INVESTORS
    • News & Media
    • Partners
  • Footer Aside Section 2
    • Healthcare Professionals
    • Business To Business
    • Change Region
    • Sitemap
  • Footer Aside Section3
    • Twitter
    • Facebook
    • Linkedin
    • Instagram
    • Youtube
  • Footer Aside Section4
    • Contact Us
    • Terms of Use
    • Privacy Policy
Pfizer Logo Footer

Copyright © 2002-2021 Pfizer Inc. All rights reserved. This information—including product information—is intended only for residents of the United States.
The products discussed herein may have different labeling in different countries.